Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- Wall St falls as tech losses, Middle East tensions deepen
- Oil prices rise after Trump says Iran must pay price
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Has Tesla solved the self-driving puzzle? This analyst thinks so
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Micron to deliver 'another strong quarter', Goldman says
- UK's Ofcom requires tech firms to create crisis response plans
- Supermicro plans $7 billion financing to fund AI server orders
Evercore ISI Upgrades Vertex (VRTX) to Outperform
April 11, 2024 6:01 AM EDTEvercore ISI analyst Liisa Bayko upgraded Vertex (NASDAQ: VRTX) from In Line to Outperform with a price target of $438.00.
The analyst comments "In a surprise move (but makes all the sense now), VRTX is acquiring ALPN, a company focused on developing protein-based... More
